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Abstract
Heavy metals have been used in a wide variety of human activities that have significantly increased both professional and 
environmental exposure. Unfortunately, disasters have highlighted the toxic effects of metals on different organs and systems. 
Over the last 50 years, the adverse effects of chronic lead, mercury and gadolinium exposure have been underscored. Mercury 
and lead induce hypertension in humans and animals, affecting endothelial function in addition to their other effects. Increased 
cardiovascular risk after exposure to metals has been reported, but the underlying mechanisms, mainly for short periods of 
time and at low concentrations, have not been well explored. The presence of other metals such as gadolinium has raised 
concerns about contrast-induced nephropathy and, interestingly, despite this negative action, gadolinium has not been defined 
as a toxic agent. The main actions of these metals, demonstrated in animal and human studies, are an increase of free radical 
production and oxidative stress and stimulation of angiotensin I-converting enzyme activity, among others. Increased vascular 
reactivity, highlighted in the present review, resulting from these actions might be an important mechanism underlying increased 
cardiovascular risk. Finally, the results described in this review suggest that mercury, lead and gadolinium, even at low doses 
or concentrations, affect vascular reactivity. Acting via the endothelium, by continuous exposure followed by their absorption, they 
can increase the production of free radicals and of angiotensin II, representing a hazard for cardiovascular function. In addition, 
the actual reference values, considered to pose no risk, need to be reduced.
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Historical background
The use of heavy metals is intimately connected to 
human history. Men discovered metals as important ma-
terials for making tools and implements as early as during 
prehistorical times. However, recorded information about 
metals does not simply describe their benefits. The contacts 
of human beings with metal compounds that have no physi-
ological activity, even at low concentrations, are correlated 
to high levels of toxicity (1). Nowadays several industrial 
activities and agriculture generate a wide variety of chemical 
species containing lead, mercury and cadmium, which are 
in general associated with environmental pollution because 
of their toxicity and bioaccumulation (1). Metals are also 
used as ingredients in several compounds for treatments, 
conservation of vaccines (2) or contrast medium, as is the 
case for gadolinium (3).
These metals usually induce free radical production and 
mainly interact with sulfhydryl groups in proteins, altering 
their activities. The biochemical basis for these effects is 
often attributed to the inhibition of several ATPases, including 
Na,K-ATPase (NKA) and Ca-ATPase (4-8), angiotensin I-
converting enzyme (ACE), and to the production of oxidative 
damage (free radicals by activation of NADPH oxidase). 
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Damage resulting from acute or chronic exposure to toxic 
metals has been mainly described for the nervous system 
and kidneys (4,8-10). However, increasing knowledge 
about vascular function including the endothelial-derived 
mechanisms that regulate vascular tone and the role of 
enzymes, such as NKA and ACE, and free radicals, has 
mainly been obtained about metals with vascular function 
that promote endothelial dysfunction, hypertension and 
vascular diseases. Recently, the fact that the endothelium 
is affected by low doses or concentrations of heavy metals 
has highlighted the importance and the need of improved 
knowledge of the mechanisms by which these metals pro-
mote the development of cardiovascular diseases.
In this review, we will focus on the vascular actions of 
mercury, lead and gadolinium, heavy metals that we have 
been studying in our laboratory.
Mercury
Mercury is worthy of note in this context because of 
its high toxicity and great mobility in ecosystems. Mercury 
is known to exert its effects by combining with SH groups 
(4,11), which are essential for the normal function of several 
proteins that constitute enzymes, ion channels or receptors 
(11,12). These effects include inhibition of ATP hydrolysis 
and NKA and Ca2+-ATPase activity (5,7).
The US Environmental Protection Agency recommends 
the reference blood concentration of mercury to be below 
that considered without adverse effects, which is 5.8 ng/mL 
(13). However, in unexposed populations taken as controls, 
blood mercury concentration was reported to be 2.73 ng/
mL in New York City adults and 1 ng/mL in China (14,15). 
For many years mercury was used in diuretics or as an 
ingredient of antiseptics (4). However, after mercurials were 
replaced with more specific treatments, signs of mercury 
intoxication have become rare (10). However, in the past 
decade, mercury intoxication and poisoning attained high 
levels (9,16,17) as a result of environmental pollution. The 
Minamata Bay episode resulting from industrial plastic 
disposal, the ingestion of contaminated wheat seeds in 
Guatemala, Iraq and Pakistan, and contamination from 
metallic mercury used in gold mining in Brazil are examples 
of this problem (1,17). Human toxicological data about 
methylmercury poisoning show that symptoms of toxic ef-
fects appear at a concentration of mercury in blood of 0.1 
µg/mL and death occurs at concentrations above 3 µg/mL 
(9). It has also been reported that professional exposure to 
mercury vapor and the release of mercury from or during the 
removal of amalgam dental fillings increases the blood and 
plasma concentration of the metal (18-20). After exposure to 
mercury vapor, blood concentrations attain 18 nM (20) and, 
after exposure to dental amalgam fillings and their removal, 
plasma concentration attains 5 nM (19). Another important 
mechanism of exposure is fish consumption. Mercury attains 
5.65 ng/mL among regular fish consumers (13,14) and levels 
of 7 to 10 ng/mL among exposed workers (10,15).
Recently, more attention has been paid to the toxic 
effects of mercury on the cardiovascular system and their 
association with hypertension, carotid atherosclerosis, 
myocardial infarction, and coronary heart disease (21-23). 
In the cardiovascular system, acute mercury exposure 
promotes reduction of myocardial force development (24) 
and inhibition of myosin ATPase activity (24). Chronic ex-
posure to this metal increases vascular resistance (25,26) 
and induces hypertension (21).
Functional integrity of the endothelium is crucial for 
the maintenance of blood flow and antithrombotic capac-
ity because the endothelium releases humoral factors that 
control relaxation and contraction, thrombogenesis and 
fibrinogenesis and platelet activation and inhibition. Previ-
ous studies have demonstrated that mercury decreases the 
production of nitric oxide (NO) and alters the expression of 
NO synthase (NOS) (27). HgCl2 at concentrations of 0.5 
to 10 µM produces vasoconstriction, reduces the endothe-
lial vasodilator response and stimulates a cyclooxygenase 
(COX)-derived vasoconstrictor (28). In addition, several 
studies have shown that mercury induces oxidative stress 
with subsequent oxidative damage to several organs or 
systems (23). Glutathione (GSH) depletion by mercury 
may be a trigger for the production of reactive oxygen 
species (ROS) that induce lipid, protein and DNA oxidation 
(23). Vascular endothelium is highly sensitive to oxidative 
stress and this is the main cause of endothelial dysfunction 
observed in cardiovascular diseases such as hypertension 
and atherosclerosis (22,29). Most mercury toxicity studies 
are performed with high (micromolar) concentrations of 
mercury and under acute exposure. Then, given the idea 
that relatively high blood levels are more frequently used to 
indicate mercury as an environmental risk factor for cardio-
vascular diseases, we recently developed a methodology 
involving controlled chronic mercury administration that 
attains a concentration of 8 ng/mL (~29 nM) in blood (25) 
to better understand the endothelial modulation of vascular 
responses.
Lead
Lead is abundant in the earth’s crust, with average 
concentrations between 10 and 20 mg/kg in the soil. The 
greatest natural sources are volcanic activity and geochemi-
cal weathering. It is estimated that the natural emissions of 
lead are about 19,000 tons. However, anthropogenic pro-
cesses such as painting, addition of lead to petrol, battery 
manufacturing, etc., are important processes responsible 
for the environmental presence of lead (30). Once lead 
particles go into the air they are removed by deposition, 
transferred to the surface and rapidly distributed in water 
or sediments according to the pH of dissolved salts (30). 
Therefore, lead has become one of the most common en-
vironmental contaminants resulting from external sources. 
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This metal is recognized as a common environmental and 
occupational health hazard (31) because of numerous 
industrial activities that favor its wide distribution. Human 
beings usually have lead in their organism (8) which, upon 
sufficient exposure and/or accumulation in the body (32,33), 
can exert adverse effects. Although having no physiologi-
cal function, its toxic effects on humans and animals have 
long been known, affecting almost all organs and systems 
in the human body. 
The effects of lead on human health depend on plasma 
levels and on the duration of exposure. Blood lead levels 
up to 29 µg/dL (1 to 1.4 µM) led to a 46% increase in all-
cause mortality, a 39% increase in circulatory mortality 
and a 68% increase in cancer mortality (34). In addition, 
chronic exposure to low levels of lead causes hyperten-
sion in animals and humans (33,34). Vupputuri et al. (35), 
when re-evaluating the results of the Third National Health 
and Nutrition Examination Survey (36), reported a positive 
correlation between plasma lead concentration and arterial 
pressure in black men and women. 
The limit of blood lead concentration recommended 
by the Agency for Toxic Substances and Disease Registry 
(31) is 60 µg/dL in occupationally exposed adults. How-
ever, an increase in arterial pressure has been reported 
for individuals with blood lead concentrations of 31.4 and 
53.5 µg/dL (35-37). Previous studies on lead toxicity have 
reported 42.5 ± 2.3 and 58.7 µg/dL (38,39), blood concen-
trations that are similar to those found in the occupation-
ally exposed population. In Brazil (Ministério do Trabalho; 
Norma Regulamentadora No. 7), the reference values for 
blood lead concentrations have been established at 40 
µg/dL for unexposed persons and at 60 µg/dL for exposed 
persons. 
A close relationship between lead exposure and hy-
pertension has been reported in experimental studies on 
animals and in epidemiological reports (8). Lead-induced 
hypertension is reported to result from the inhibition of NKA 
(39) and from the reduced bioavailability of NO plus an 
increased endothelial release of endothelin (40,41). Free 
radicals reducing NO bioavailability (42) and depletion of 
antioxidant reserves (8,43) or their up-regulation (39) have 
also been reported. Peripheral or central nervous mecha-
nisms, such as the increase of sympathetic nerve activity, 
the reduction of baroreflex sensitivity and the reduction of 
parasympathetic tone (33), are also involved in lead-induced 
hypertension. In addition, Carmignani et al. (32,41) reported 
increased myocardial inotropism and increased ACE activity 
in rats exposed to 60 ppm lead acetate for 10 months. 
Previous studies have shown that possible mechanisms 
involved in lead-induced hypertension are due to alterations 
in vascular tone (8,39). Changes in vascular reactivity have 
not been extensively described in the presence of low lead 
concentrations and in the initial stages of lead exposure. 
However, studies have shown that chronic exposure to low 
lead concentrations induces aorta vasoconstriction (44). 
On the other hand, chronic exposure to lead (100 ppm for 
10 months) decreased the contractile response induced 
by 5-hydroxytryptamine (5-HT) in the aorta of lead-treated 
rats (45). These effects could be mediated by increased 
production of ROS and vasoconstrictor prostanoids of the 
cyclooxygenase pathway (26,39).
Gadolinium
Gadolinium is a trivalent lanthanide cation currently used 
as a magnetic resonance contrast medium, the gadobenate 
dimeglumine (Gd-bopta) (3), which blocks calcium chan-
nel stretch at high concentrations (10 µM) (46). However, 
concerns about contrast-induced nephropathy have been 
reported (47). 
In addition to acting as a calcium channel blocker, gado-
linium, at low concentration, can interact with the signaling 
involved in intracellular and extracellular ATP hydrolysis 
(48). Escalada et al. (49) reported that 3 µM gadolinium, 
a concentration that does not block calcium channels, has 
a potent inhibitory action on ecto-nucleoside triphosphate 
diphosphohydrolase (E-NTPDase) activity from the electric 
organ of Torpedo marmorata. Extracellular nucleotides are 
important molecules involved in the regulation of different 
biological processes including vascular tone. When released 
as a neurotransmitter from the sympathetic terminals, ATP 
binds to P2X receptors of vascular smooth muscle cells, 
producing vasoconstriction. When binding to endothelial 
P2Y receptors, ATP leads to vasodilatation (48,50). ATP 
exerts other effects on the vascular beds, such as control 
of smooth muscle and endothelial cell proliferation (48,50). 
The action of extracellular nucleotides is terminated by the E-
NTPDase family. NTPDase1 is the major ectonucleotidase 
expressed in the vasculature (48,50) and its action limits 
platelet activation by ATP hydrolysis (48,50). NTPDase2 is 
another ectonucleotidase associated with the vasculature 
that preferentially converts ATP to ADP (50). Following the 
action of E-NTPDases, ecto-5’-nucleotidase is responsible 
for the end of nucleotide signaling by converting AMP to 
adenosine (51).
Gadolinium also affects ACE activity as a chelate by 
a transmetallation effect with zinc (52). This enzyme is a 
metallopeptidase containing zinc and therefore the pos-
sibility of a transmetallation effect is likely. Angiotensin II 
resulting from the action of ACE is the major effector of 
the renin-angiotensin system (RAS) (53). It activates the 
AT1 receptor, has vasoconstriction and pressor effects and 
also causes thrombosis, inflammation and vascular and 
myocardial hypertrophy (53).
Interestingly, despite these actions, gadolinium has not 
been defined as a toxic agent. There is no toxicological 
information and recommended exposure limits have not 
been defined.
After describing the main characteristics of mercury, 
lead and gadolinium and considering that mercury and lead 
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are known to produce hypertension and gadolinium affects 
the RAS, we will focus on actions of these three metals on 
vascular reactivity. Their effects will be briefly described in 
protocols that are commonly employed in several labora-
tories mainly using vascular rings.
Effects of heavy metals on vascular 
reactivity
Changes in vascular responses to phenylephrine
We used the following protocol to test the general 
characteristics of vascular reactivity. Rats are anesthetized 
with sodium thiopental (50 mg/kg, ip) and killed by exsan-
guination. Thoracic aortas are removed and placed in cold 
oxygenated Krebs-Hanseleit bicarbonate buffer (KHB), 
carefully dissected out and cleaned of fat and connective 
tissue. For reactivity experiments, the aortas are divided 
into cylindrical segments 4 mm in length and cut into rings 
4-6 mm in length. Rings are then mounted between parallel 
wires in tissue baths at 37°C containing KHB gassed with 
95% O2 and 5% CO2 to maintain the pH at 7.4. However, 
for lead (as lead acetate) the bicarbonate buffer cannot 
be used because it precipitates. pH can be adjusted with 
20 mM HEPES plus 4 mM NaOH. Rings are stretched to 
an optimal resting tension of 1 g and isometric tension is 
recorded using an isometric force displacement transducer. 
After 45-min equilibration each aortic ring is exposed twice 
to 75 mM KCl to obtain its maximum contractility. Rings are 
then sequentially washed and re-equilibrated and allowed 
to relax to baseline. Thirty minutes later, the rings are con-
tracted with 1 µM phenylephrine and 10 µM acetylcholine 
(ACh) is then added to assess the integrity of the endothe-
lium. A relaxation equal to or greater than 90% indicates 
functional integrity of the endothelium. Smooth muscle 
viability is tested using sodium nitroprusside (SNP, 0.1 
mg/mL) in rings previously contracted with phenylephrine. 
After 30 min, cumulative concentration-response curves for 
phenylephrine (0.1 nM-300 µM) are generated.
The incubation of segments with mercury (HgCl2) for 60 
min promotes an increase in the reactivity to phenylephrine 
both at high (0.5 to 10 µM) and low (6 nM) concentrations 
(54,55). This increased reactivity appears as an increased 
Rmax and sensitivity. Gadolinium (3 µM as GdCl3) promotes 
similar responses (56) but lead increases vascular reactivity 
when administered only at high concentration (100 µM). At 
lower lead concentration (5 nM), reactivity to phenylephrine 
decreases.
When controlled chronic mercury treatments are per-
formed using exposure to low doses for 30 days, with a 
blood concentration of 8 ng/mL (~29 nM) being reached, 
vascular reactivity to phenylephrine increases in Hg-treated 
rats (25,26). Mercury treatment also increases 5-HT-induced 
vasoconstriction in coronary arteries (27). A similar increase 
of vascular reactivity was obtained with lead treatments 
for 30 days or more (57). However, exposure of rats to low 
lead concentrations for 7 days decreased the contractile 
response of aortic rings to phenylephrine (58). These find-
ings confirm previous reports clearly suggesting that the 
effects of lead are concentration and time dependent (32). 
Regarding gadolinium, there are no reports about chronic 
treatments with low concentrations.
Role of the endothelium in the effects of mercury, 
lead and gadolinium
To evaluate its role in the vascular effects of heavy 
metals, the endothelium is removed by gently rubbing the 
intimal surface with a stainless steel rod. The effectiveness 
of endothelial removal is confirmed by the absence of the 
relaxation induced by 10 µM Ach in aortic segments pre-
contracted with 1 µM phenylephrine. Removal is considered 
to be adequate when Ach-induced relaxation is less than 
10% or a contraction is observed. 
Removal of the endothelium increases vasoconstrictor 
responses or rat aortic segments to phenylephrine. This 
indicates that the vascular response to phenylephrine is 
negatively modulated by the endothelium. The effects on 
the phenylephrine response of all three metals, acutely ad-
ministered, were dependent on the integrity of this vascular 
layer. Thus, when the endothelium is removed their actions 
are abolished (25,56,57). This endothelial dependence is 
observed for low and high concentrations of mercury and 
lead. The only effect reported thus far for gadolinium was 
obtained with a concentration of 3 µM (56). 
The effects on the phenylephrine response observed 
with chronic administration of low concentrations of mercury 
and lead also show endothelial dependence because en-
dothelial removal abolishes the effects of both metals. The 
effects of mercury and gadolinium, which increase vascular 
reactivity to phenylephrine, are abolished by endothelium 
removal and the reduced vascular reactivity to phenyleph-
rine observed for lead is also abolished. 
Effects of mercury, lead and gadolinium on 
endothelial modulation of vascular responses to NO
The NOS inhibitor NG-nitro-L-arginine methyl ester (L-
NAME, 100 µM) is commonly used to test the endothelial 
modulation of vascular responses to NO. L-NAME has 
a potentiating effect on the vasoconstrictor response to 
phenylephrine, which indicates the negative endothelial 
NO modulation of such response. The results also give 
information about NO bioavailability. This is important to 
consider because we can have an enhanced NO produc-
tion which, however, can be destroyed, reducing bioavail-
ability. To better explain this issue some protocols can be 
performed such as analysis of production blockade, NO 
production stimulated with Ach, definition of which NOS 
(eNOS, nNOS, and iNOS) are involved, and which factors 
are destroying NO.
Acute administration of 6 nM HgCl2 reduces the nega-
tive endothelial modulation of phenylephrine responses 
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(54). However, the endothelial modulation is increased 
after acute lead treatment, suggesting that the endothelium 
tries to adapt to the new environmental conditions and that 
the increased reactivity depends on factors other than NO 
production. Regarding the effects of gadolinium, L-NAME 
treatment in the presence of gadolinium does not change 
the reactivity to phenylephrine. This finding suggests that the 
increased vascular reactivity increment does not depend on 
NO but depends on another endothelial-derived factor.
Chronic treatments have been reported for mercury and 
lead but not for gadolinium. Mercury reduces the effect of L-
NAME effect, as seen with endothelial denudation. However, 
lead treatment for 7 days enhanced endothelial modulation 
by NO, which would explain the reduced phenylephrine 
responses observed after lead treatment. Our findings 
suggest that this increased NO production is dependent 
on an increased activity of eNOS and iNOS.
Effects of mercury, lead and gadolinium on the 
endothelial modulation of vascular responses by 
prostanoids
Prostaglandins are endothelial factors that participate 
in vascular responses. The involvement of prostanoids in 
phenylephrine responses was investigated using 10 µM 
indomethacin, a well-known non-selective COX inhibitor.
Indomethacin reverses the increased reactivity to 
phenylephrine induced by acute administration of 6 nM 
HgCl2 (54). Chronic treatment also induces the same re-
sponse caused by an increased production of contractile 
prostanoids (prostaglandin 2 and thromboxane A2) derived 
from COX-2.
Similar effects are also promoted by a high concentration 
of lead acetate (100 µM). However, under low lead concen-
trations indomethacin does not alter the pressor effects of 
phenylephrine, suggesting that prostanoids do not play a 
role in the actions of lead (58). The effects of gadolinium 
on COX activity have not been described.
Effects of mercury, lead and gadolinium on 
endothelial modulation of vascular responses to 
endothelial-derived hyperpolarizing factors 
Endothelial-derived hyperpolarizing factors (EDHFs) 
are important vasodilator agents that act by increasing the 
permeability of K+ channels. Tetraethylammonium (TEA, 
1 to 5 mM) is commonly used to test the dependence on 
hyperpolarizing factors. TEA blocks several potassium 
channels and is used as a first attempt to define the role 
of these channels in an intervention with toxic metals, for 
example. Instead of a single one, several compounds are 
considered to be EDHFs. NO, epoxyeicosatrienoic acids, 
anandamide, and even H2O2 have been described as 
EDHFs depending on the vascular bed studied. 
Mercury and lead indirectly affect EDHF production 
because both can reduce NO bioavailability, inducing free 
radical generation (8,25,26). A short-term exposure to low 
lead concentrations, however, reduces vascular reactivity 
and seems to stimulate K+ channels in vascular smooth 
muscle cells (58). Again, the effects of gadolinium on EDHF 
activity have not been described.
Role of free radicals in the effects of mercury, lead 
and gadolinium on vascular responses
Several compounds can be used to investigate the 
possibility that free radicals play a role in the effects of 
mercury, lead or gadolinium on the pressure response to 
phenylephrine: tempol, an agent that mimics superoxide 
dismutase (4-hydroxy-tempo, 1 µM); deferoxamine, a free 
radicals scavenger (300 µM); the superoxide anion scavenger 
superoxide dismutase (SOD, 150 U/mL); catalase (1000 U/
mL), a scavenger of H2O2, and the NAD(P)H oxidase inhibitor 
apocynin (0.3 mM). The oxidative fluorescent dye dihydro-
ethidium (DHE) is used to evaluate O2.- production in situ 
(59). Inside the cells, hydroethidine is oxidized to ethidium 
bromide in the presence of O2.- because it freely permeates 
cells and is then trapped by intercalation with DNA.
Mercury at low and high concentrations stimulates free 
radical generation after both acute and chronic treatment. 
This increased free radical generation is usually respon-
sible for the reduction of NO bioavailability. Thus, we have 
observed that: 1) vascular O2.- production and plasma 
oxidative stress are greater in rats treated with mercury 
chloride, 2) mercury treatment also increases vascular 
mRNA levels of the NAD(P)H oxidase subunits NOX-1 
and NOX-4 (27), and 3) several antioxidants abolish the 
increased vasoconstrictor responses observed in vessels 
from mercury-treated rats (25,27). 
Lead is also described as an inducer of free radical 
production (8). The metal increases superoxide production 
and the blockade of its effects by SOD, catalase and apo-
cynin shows a reduction of reactivity in the dose-response 
curve to phenylephrine. These findings also suggest that 
NADPH oxidase is also a putative site for the effect of lead 
in increasing free radical generation.
Effects of mercury, lead and gadolinium on ACE 
activity
The RAS plays an important role in the regulation of the 
cardiovascular system. The RAS was initially described as 
systemic RAS but a local RAS has been recently described 
in several tissues. The classic RAS depends on the ac-
tion of renin. This enzyme changes angiotensinogen to 
angiotensin I that is converted to angiotensin II by ACE. 
ACE is an enzyme that has two zinc atoms in its molecule, 
which can be changed by other metals by a transmetalla-
tion process.
The participation of the RAS in the concentration-
response curve to phenylephrine was studied in control 
or treated preparations by the blockade of ACE or the AT1 
angiotensin II receptor with 1 µM enalaprilate and 10 µM 
losartan, respectively. When the AT1 receptor is blocked, 
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angiotensin II is present and its effects on AT2 receptors 
might take place because they are operational. When ACE 
is blocked by enalaprilate, no angiotensin II is produced. 
Then, if the action of the metals is blocked, it suggests that 
ACE is being stimulated by the metals. The effects of all 
three metals are blocked when both drugs are used.
A curious finding is that when low concentrations of 
these metals are used ACE is stimulated. However, when 
high concentrations of mercury and gadolinium are used 
ACE is blocked (52). These effects have one interesting 
explanation, i.e., the transmetallation phenomenon (52). 
ACE has zinc attached to both active sites, which can 
be changed by other metals. The fact that at higher con-
centrations ACE is inhibited is also explained by another 
phenomenon called hormesis (60). Hormesis explains why 
toxic agents and venoms can activate or reduce their ef-
fects and as concentrations change the effects turn in the 
opposite direction.
As a final remark, the findings presented here suggest 
that mercury, lead and gadolinium, even at low doses or 
concentrations, affect vascular reactivity. Their actions are 
mediated by the endothelium and result mainly from an 
enhanced production of free radicals and an increased pro-
duction of angiotensin II by stimulation of the local ACE. The 
findings reported here provide further evidence that toxic 
metals, even at low doses, could be an environmental risk 
factor for cardiovascular disease.
These results also suggest that continuous exposure to 
these metals followed by their absorption may be hazardous 
to cardiovascular function and the current reference values, 
considered to be without risk, need to be reduced.
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